ArticleBMC ophthalmology2025
Preliminary insights into serum metabolomics in atrophic myopic maculopathy: potential link to fatty acid metabolism dysregulation.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic challenges in high myopia: identification of sight-threatening complications and the role of artificial intelligence.Frontiers in ophthalmology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAtrophic myopic maculopathy (AMM) causes irreversible and progressive visual impairment. Metabolomics offers a valuable opportunity for exploring the pathological mechanisms of AMM and identifying potential therapeutic targets. This study compared serum metabolite profiles between patients with high myopia with and without AMM.
methodsThis case-control study included 57 adults with high myopia (30 with AMM, 27 without AMM). Clinical data including body mass index (BMI), fasting blood glucose, and lipid profiles were recorded. Serum samples were analyzed using untargeted metabolomics based on ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Differential metabolites were first screened for their discriminative performance using receiver operating characteristic (ROC) curves. Weighted gene co-expression network analysis (WGCNA) was then applied to explore co-expression patterns and identify metabolite modules associated with clinical traits. Multivariate logistic regression was performed to identify independent metabolic predictors of AMM.
resultsCompared with controls, patients with AMM showed significant alterations in serum metabolites, including 18 upregulated and 26 downregulated compounds, enriched in 5 pathways. WGCNA and ROC analysis identified 11 potential biomarkers associated with atrophy grades in AMM. Three metabolites were independently associated with AMM after adjustment: triglyceride (OR = 2.73, p = 0.021), ln[Tetracosahexaenoic acid] (OR = 3.54, p = 0.004), and ln[Decanoylcarnitine] (OR = 0.37, p = 0.025). The model showed good fit (χ² = 22.89, p < 0.001) with 71.9% accuracy and AUC = 0.821 (95% CI: 0.715-0.927).
conclusionsThis study provides exploratory evidence of dysregulated serum fatty acid metabolism in AMM. These findings suggest that such metabolic alterations may be associated with mitochondrial dysfunction and inflammatory processes, offering a potential direction for future mechanistic and therapeutic research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.